Elaborate training will have a positive longterm effect on the longitudinal measurement properties of the PDASII.
ID
Bron
Verkorte titel
Aandoening
Rheumatoid Arthritis, reumatoïde artritis, patient reported outcomes, patiënt gerapporteerde uitkomsten, self assessed joint counts, zelfonderzoek, training,PDASII, validation, validatie, clinimetrics, klinimetrie
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Concurrent longitudinal validity of the PDASII with the DAS28 at 6, 9 and 12 months follow-up by means of a random effect model with training yes/no as a independent variable.
Achtergrond van het onderzoek
Background:
In recent years there has been a trend in medical practice towards patient-centred care. Within rheumatology attention is being paid to finding outcome measures with which patients with Rheumatoid Arthritis (RA) can track their disease process; hereby exploring effective and efficient ways to evaluate therapy.
Objective:
The objective of this study is:
1. To assess the measurement properties of a RA disease activity score based on patients’ self assed joint scores, and;
2. To assess the effect of training on these measurement properties.
Methods:
For this study we will include a broad range of RA patients, who are seen in daily clinical practice. Patients seen three months after being diagnosed and patients switching to immune modulating therapy will be invited to take part in this study. Patients will be randomised to receive joint count training or not, and will be followed for one year. In this follow up period the various measures will be collected such as: the Disease Activity Score 28 joint count (DAS28), the Clinical Disease Activity Index (CDAI), the patient-based Disease Activity Score version two (P-DASII), as well as other patient reported outcomes, such as the Health Assessment Questionnaire Disability Index (HAQ-DI), the Routine Assessment of Patient Index Data (RAPID 2-5), the modified Rheumatoid Arthritis Disease Activity Index (RADAI-5), the Patient derived Disease Activity Score 28 joint count (Pt-DAS28), the Short Form 36 Health Survey (SF-36) and Euroqol 5D (EQ-5D). In addition to these measures, radiographs of the hands and feet will be taken at baseline and 12 months follow-up to assess joint damage progression.
Validity will be investigated by comparing the course of the PDASII and the other measures over time. Reliability of the self assessed joint counts will be investigated by obtaining these measures twice, with a two day separation period (test-retest). Sensitivity of the PDASII will be assessed and compared to the sensitivity of the DAS28 and CDAI. The effect of training will be analysed by performing the analyses with training as a covariate.
Results:
Data from this study will elucidate the value of patient reported outcomes for the monitoring of treatment. Based on this information a monitoring strategy can be developed, where effectiveness, cost effectiveness, patient participation and time efficiency will be optimised. Ultimately this will lead to patient care, where patients’ interests and participation are central and where clinical measurement instruments and physicians’ expertise are optimally utilized to achieve the best possible results.
Doel van het onderzoek
Elaborate training will have a positive longterm effect on the longitudinal measurement properties of the PDASII.
Onderzoeksopzet
Patients are followed for one year at regular three monthly visits.
Onderzoeksproduct en/of interventie
Standard joint assessment instructions vs elaborate joint assessment training by means of extended written instructions including photographs, an instructional video on the performance of self-assessment of the joints and two verbal feedback sessions with a trained research nurse at baseline and three months follow-up.
Publiek
Jos Hendrikx
UMC St Radboud
Geert Grooteplein 8
Afdeling reumatische ziekten (huispost 470)
Nijmegen 6500 HB
The Netherlands
+31 (0)24 3617547
J.Hendrikx@reuma.umcn.nl
Wetenschappelijk
Jos Hendrikx
UMC St Radboud
Geert Grooteplein 8
Afdeling reumatische ziekten (huispost 470)
Nijmegen 6500 HB
The Netherlands
+31 (0)24 3617547
J.Hendrikx@reuma.umcn.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Early RA patients seen 3 months post diagnosis or;
2. Patients starting on immunomodulating therapy (biological).
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1.Patients younger than 18 years of age;
2.Patients totally incapable of performing the PDASII evaluation;
3.Patients unwilling to be randomised between training groups.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL2510 |
NTR-old | NTR2628 |
Ander register | CMO regio Arnhem Nijmegen : 2010/300 |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |